Method for the treatment of Dravet syndrome

Patent metadata

Field	Value
Publication number	US-9603815-B2
Application number	US-201615003161-A
Country	US
Kind code	B2
Filing date	Jan 21, 2016
Priority date	May 3, 2013
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.

First claim

The invention claimed is:

1. A method of treating seizures in a patient diagnosed with Dravet syndrome, comprising:
administering to the patient diagnosed with Dravet Syndrome a therapeutically effective dose of a 5-HT2C agonist;
administering an effective dose of stiripentol or a pharmaceutically acceptable salt thereof to said patient;
administering an effective dose of valproate or a pharmaceutically acceptable salt thereof to said patient;
administering an effective dose of clobazam or a pharmaceutically acceptable salt thereof to said patient; and
allowing the 5-HT2C agonist to stimulate 5-HT2C receptors in the patient and thereby reduce seizures in the patient, wherein the 5-HT2C agonist is fenfluramine.

2. The method of claim 1 ,
wherein the therapeutically effective dose of fenfluramine is 0.5 mg/kg/day to 0.01 mg/kg/day, and
wherein the patient is aged 18 or less.

3. The method of claim 1 , wherein the therapeutically effective dose of fenfluramine is administered in a dosage form selected from the groups consisting of oral, injectable, transdermal, inhaled, nasal, rectal, vaginal and parenteral.

Assignees

• Univ Leuven Kath
• Univ Hospital Antwerp
• The Katholieke Univ Leuven

Inventors

• Ceulemens Berten
• Lagae Lieven

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title

• A61K31/19

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title

• A61K31/135

  having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title